Penserra Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Penserra Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-940	Closed	-$14K	–	1570
2021 Q3	$14K	Buy	940 +5	+0.5%	+$87	﹤0.01%	1305
2021 Q2	$17K	Buy	935 +140	+18%	+$2.58K	﹤0.01%	1189
2021 Q1	$14K	Sell	795 -10	-1%	-$169	﹤0.01%	1002
2020 Q4	$12K	Buy	+805	New	+$9.42K	﹤0.01%	910

Other funds holding XENE

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Penserra Capital Management's XENE Position: Q4 2021 in Review

Penserra Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q4 2021, closing a stake of 940 shares — an estimated $14K sold.

Penserra Capital Management first reported a position in XENE in Q4 2020 and held it in 4 quarters. The position peaked at $17K in Q2 2021. 130 funds tracked by Wall St. Rank hold XENE as of Q4 2021.

Penserra Capital Management reported no remaining Xenon Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Penserra Capital Management sold 940 Xenon Pharmaceuticals shares in Q4 2021, an estimated $14K.
Penserra Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2020 and held it in 4 quarters.
Penserra Capital Management's Xenon Pharmaceuticals position peaked at $17K in Q2 2021.
130 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.